Drug intelligence / Profile preview

Path-001

Development stage: Preclinical
Lead developer: PATH Biotech
Modality: Small Molecules

Overview

Path-001 is a small molecule drug candidate being developed by PATH Biotech for the treatment of Alzheimer's disease. Discovered using the company's AI-driven precision medicine platform, the candidate is currently in the preclinical stage of development. PATH Biotech focuses on leveraging AI to identify novel treatments for neurodegenerative diseases, cancer, and auto-immune disorders. As of early 2024, the specific molecular target and mechanism of action for Path-001 have not been publicly disclosed.

Beyond the preview

Go deeper on Path-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Path-001.

Explore the full profile